Latest Hotspot

Bioscience Replication begins a Phase 1 Study for its upcoming srRNA Vaccine

19 September 2023
3 min read

Replicate Bioscience, an advanced-stage firm specializing in the innovative self-copying RNA technology to surpass the shortcomings of existing mRNA mechanisms and broaden the utilization of RNA therapies for infectious diseases, cancer and auto-immune conditions, announced the administration of the initial dosage to the first participant for its RBI-4000 vaccine, which is currently in Phase 1 trials and aims at preventing rabies.

👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug.

The experiment, a first-of-its-kind human application of Replicate's preeminent srRNA technology, will act as a cornerstone for practical use in this particular and other challenging infectious diseases. It will also offer fundamental knowledge to guide subsequent clinical trials, predominantly in oncology and autoimmune disease.

"Working on Rabies gives us a fantastic conduit to rapidly verify our groundbreaking vaccine technology, given the ample unexposed population and the existing protective parallels outlined by the World Health Organization," said Nathaniel Wang, Ph.D., Replicate's founder, and CEO. "Administering our first dose is a significant milestone for our enterprise as we expand our srRNA technology in various disease areas."

"Our srRNA technology presents the possibility for stronger and longer-lasting immune responses, with enhanced tolerability at lower doses when juxtaposed with existing mRNA procedures," said Zelanna Goldberg, M.D., Replicate's CMO. "In infectious disease, our srRNA technology unlocks opportunities to effectively target more intricate infectious disease symptoms and permits us to swiftly manufacture vaccine solutions to cure or defend against sickness — a valuable asset for preparing for future pandemics."

The company's first vaccine release, the RBI-4000, is an srRNA vaccine designed to prod virus-neutralizing immune reactions to rabies for prevention. The Phase 1 experiment will examine the product's safety, tolerability, and immunogenicity in 84 test subjects in the U.S. In preclinical analyses, injecting RBI-4000 intramuscularly offered sustained defense against the rabies virus, summoning antibody generation and noticeable virus-specific T cells.

👇Please click on the picture link below for free registration or login directly if you have freemium accounts, you can browse the latest research progress on drugs, targets, organizations, clinical trials, clinical results, and drug patents related to this indication.

According to the data provided by the Synapse Database, As of September 17, 2023, there are 119 investigational drugs for the Rabies, including 6 targets, 101 R&D institutions involved, with related clinical trials reaching 202and as many as 13372 patents.

Rabies remains a public health threat in several geographical regions and is designated an NIAID Priority Pathogen. The indication Rabies is highly competitive, with multiple companies, targets, drug types, and countries/locations involved in its development. China National Pharmaceutical Group Co., Ltd., Sanofi, AIM Vaccine Co., Ltd., and Poonawalla Group of Cos. are some of the companies growing fastest under this indication. The future development of the indication Rabies is promising, with ongoing research and development efforts focused on improving prevention and treatment options.

Progress in the Research of MEK Inhibitors
Progress in the Research of MEK Inhibitors
19 September 2023
MEK, or Mitogen-Activated Protein Kinase Kinase, plays a crucial role in the human body as a key component of the MAPK signaling pathway.
Read →
Pierre Fabre Laboratories acquires Vertical Bio and its innovative targeted therapy for MET-altered Non-Small Cell Lung Cancer patients
Latest Hotspot
4 min read
Pierre Fabre Laboratories acquires Vertical Bio and its innovative targeted therapy for MET-altered Non-Small Cell Lung Cancer patients
19 September 2023
Pierre Fabre Laboratories takes over Vertical Bio along with its ground-breaking, targeted therapy candidate for patients battling MET-altered Non-Small Cell Lung Cancer.
Read →
LSD1 inhibitors - A potent inhibitory target for tumor immunotherapy
LSD1 inhibitors - A potent inhibitory target for tumor immunotherapy
19 September 2023
LSD1, also known as lysine-specific demethylase 1A, is an enzyme that plays a crucial role in the regulation of gene expression in the human body.
Read →
Exelixis and Insilico Medicine Enter into an exclusive global licensing deal for ISM3091
Latest Hotspot
3 min read
Exelixis and Insilico Medicine Enter into an exclusive global licensing deal for ISM3091
19 September 2023
Insilico Medicine and Exelixis, Inc. announced a licensing agreement allowing Exelixis to globally produce and market ISM3091, a promising USP1 inhibitor related to BRCA-altered cancers.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.